Sweden's Mendus reports wider Q4 net loss, no revenue

Mendus AB (publ)

11/02/2026 07:08

Overview

Sweden's cancer immunotherapy firm reported no Q4 revenue, net loss widened yr/yr

Company raised SEK 52.5 mln through directed share issue

Company advances vididencel for myeloid leukemia, establishes large-scale production

Outlook

Mendus to start clinical trials for vididencel in CML in 2026

Company positions vididencel as post-remission therapy in AML

Mendus explores vididencel as combination treatment in ovarian cancer

Result Drivers

CLINICAL TRIAL DATA - Mendus highlighted positive long-term survival data from the ADVANCE II trial in AML, supporting vididencel as a post-remission therapy

PRODUCTION CAPABILITIES - Mendus established large-scale vididencel production with NorthX Biologics, advancing clinical development strategy

FUNDRAISING - Mendus raised SEK 52.5 mln through a directed share issue to support clinical trials and development of vididencel

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-SEK 41.08 mln
Q4 Operating Profit
-SEK 38.71 mln


Analyst Coverage

Wall Street's median 12-month price target for Mendus AB (publ) is SEK17.00, about 246.2% above its February 10 closing price of SEK4.91

Press Release: ID:nMFN3flk7s

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)